JP2024517355A5 - - Google Patents
Info
- Publication number
- JP2024517355A5 JP2024517355A5 JP2023570373A JP2023570373A JP2024517355A5 JP 2024517355 A5 JP2024517355 A5 JP 2024517355A5 JP 2023570373 A JP2023570373 A JP 2023570373A JP 2023570373 A JP2023570373 A JP 2023570373A JP 2024517355 A5 JP2024517355 A5 JP 2024517355A5
- Authority
- JP
- Japan
- Prior art keywords
- molecular weight
- weight heparin
- intermediate molecular
- use according
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2106972.9A GB202106972D0 (en) | 2021-05-14 | 2021-05-14 | Medium molecular weight heparin |
| GB2106972.9 | 2021-05-14 | ||
| PCT/EP2022/063222 WO2022238587A1 (en) | 2021-05-14 | 2022-05-16 | Medium molecular weight heparin for use in the treatment of endotheliopathy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024517355A JP2024517355A (ja) | 2024-04-19 |
| JP2024517355A5 true JP2024517355A5 (enExample) | 2025-05-26 |
Family
ID=76550734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023570373A Pending JP2024517355A (ja) | 2021-05-14 | 2022-05-16 | 血管内皮炎の治療において使用するための中間分子量ヘパリン |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240245718A1 (enExample) |
| EP (1) | EP4337225A1 (enExample) |
| JP (1) | JP2024517355A (enExample) |
| CN (1) | CN117915923A (enExample) |
| AU (1) | AU2022273186A1 (enExample) |
| CA (1) | CA3219993A1 (enExample) |
| GB (1) | GB202106972D0 (enExample) |
| WO (1) | WO2022238587A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024381335A1 (en) | 2023-11-17 | 2026-05-21 | Glycos Biomedical Ltd. | Medium molecular weight heparin |
| GB202407360D0 (en) | 2024-05-23 | 2024-07-10 | Glycos Biomedical Ltd | Functionalised medium molecular weight heparin |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1045532A1 (zh) * | 1999-06-30 | 2002-11-29 | Hamilton Civic Hospitals Research Development, Inc. | 抑制与凝结有关凝结因子的肝素成份 |
| EP3348270A1 (en) * | 2017-01-11 | 2018-07-18 | Fytagoras B.V. | Medium molecular weight heparin |
| JP2021155334A (ja) * | 2018-05-01 | 2021-10-07 | 学校法人近畿大学 | 中分子ヘパリンまたは中分子ヘパリンのアミノ酸誘導体を含む医薬組成物 |
| CN113825517A (zh) * | 2019-05-16 | 2021-12-21 | 艾克塞拉医疗公司 | 调节内皮糖萼结构的方法 |
| WO2022016098A1 (en) * | 2020-07-17 | 2022-01-20 | Xostem Ip, Inc. | Compositions and methods for treatment of inflammatory and thromboinflammatory disorders using modified exosomes |
-
2021
- 2021-05-14 GB GBGB2106972.9A patent/GB202106972D0/en not_active Ceased
-
2022
- 2022-05-16 CA CA3219993A patent/CA3219993A1/en active Pending
- 2022-05-16 WO PCT/EP2022/063222 patent/WO2022238587A1/en not_active Ceased
- 2022-05-16 AU AU2022273186A patent/AU2022273186A1/en active Pending
- 2022-05-16 JP JP2023570373A patent/JP2024517355A/ja active Pending
- 2022-05-16 EP EP22729556.5A patent/EP4337225A1/en active Pending
- 2022-05-16 CN CN202280045684.XA patent/CN117915923A/zh active Pending
- 2022-05-16 US US18/290,533 patent/US20240245718A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20100323981A1 (en) | Treatment of statin side effects | |
| AU2003224851B2 (en) | Pharmaceutical compositions containing water-soluble prodrugs of propofol and methods of administering same | |
| US10155009B2 (en) | Polyion complex of poly(L-arginine) segment-containing block copolymer and polyanionic polymer | |
| RU2012144555A (ru) | Конъюгированный фактор свертывания крови viii | |
| RU2012144554A (ru) | КОНЪЮГИРОВАННЫЙ ФАКТОР СВЕРТЫВАНИЯ КРОВИ VIIa | |
| Srinivasan et al. | Assessment of erythropoietin for treatment of anemia in chronic kidney failure-ESRD patients | |
| EP2737896B1 (en) | Umirolimus micelle for the treating cancer | |
| Biesma et al. | The efficacy of subcutaneous recombinant human erythropoietin in the correction of phlebotomy‐induced anemia in autologous blood donors | |
| WO2023240193A2 (en) | Treatment of hemophilia with fitusiran in pediatric patients | |
| Mangat et al. | Complications of chlorine inhalation in a pediatric chemical burn patient: a case report | |
| JP5881782B2 (ja) | 医薬組成物又は組合せ剤 | |
| CN116650415B (zh) | 一种靶向双重抗凋亡蛋白聚合物胶束及其制备方法与应用 | |
| CN109908356B (zh) | 负载抗肿瘤药物的氰基丙烯酸酯材料 | |
| CN102836418B (zh) | 一种平阳霉素peg-pcl-peg温敏性缓释凝胶及制备方法和应用 | |
| WO2004004794A1 (ja) | 体液適合性および生体適合性を有する樹脂 | |
| Dean et al. | Bleeding associated with concurrent warfarin and metronidazole therapy | |
| TW202342065A (zh) | 治療血友病的方法和組成物 | |
| TW202142238A (zh) | 維奈托克(venetoclax)之水溶性高分子衍生物 | |
| TN2012000562A1 (en) | Sustained-release formulation | |
| Trinder et al. | Propofol and alfentanil total intravenous anaesthesia: a comparison of techniques for major thoracic surgery | |
| Shaban et al. | Role of gabapentin in controlled hypotension for nasal surgeries: a randomized controlled study | |
| JP6347899B2 (ja) | 腫瘍転移を低減する修飾グルコースポリマーの混合物の使用 | |
| Watanabe et al. | Decrease in circulating hematopoietic progenitor cells by trapping in the pulmonary circulation | |
| Choudhury et al. | In terms of analgesic requirements—a comparison between laparoscopic nephrectomy and open nephrectomy | |
| BRANCH | PROSPECTIVE RANDOMISED COMPARATIVE STUDY OF EFFICACY OF COMBINATION OF TRANEXAMIC ACID AND ETHAMSYLATE BY ORAL AND INTRAVENOUS ROUTES IN RELATION TO CONTROL OF BLEEDING IN CARDIAC SURGERIES. |